Czech National Bank Raises Stock Holdings in Stryker Corporation $SYK

Czech National Bank increased its stake in Stryker Corporation (NYSE:SYK) by 3.9% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 87,389 shares of the medical technology company’s stock after purchasing an additional 3,316 shares during the period. Czech National Bank’s holdings in Stryker were worth $32,305,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of the stock. Brighton Jones LLC lifted its holdings in shares of Stryker by 15.4% during the 4th quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company’s stock worth $1,643,000 after acquiring an additional 609 shares during the last quarter. Legacy Financial Advisors Inc. lifted its stake in Stryker by 9.1% during the first quarter. Legacy Financial Advisors Inc. now owns 1,199 shares of the medical technology company’s stock worth $446,000 after purchasing an additional 100 shares during the last quarter. Venture Visionary Partners LLC boosted its holdings in shares of Stryker by 10.6% in the 1st quarter. Venture Visionary Partners LLC now owns 4,273 shares of the medical technology company’s stock worth $1,591,000 after purchasing an additional 410 shares in the last quarter. Humankind Investments LLC increased its position in shares of Stryker by 4.7% during the 1st quarter. Humankind Investments LLC now owns 4,524 shares of the medical technology company’s stock valued at $1,684,000 after purchasing an additional 204 shares during the last quarter. Finally, Erste Asset Management GmbH raised its holdings in shares of Stryker by 20.3% during the 1st quarter. Erste Asset Management GmbH now owns 123,026 shares of the medical technology company’s stock valued at $45,260,000 after buying an additional 20,736 shares in the last quarter. 77.09% of the stock is currently owned by institutional investors.

Stryker Trading Up 0.3%

NYSE:SYK opened at $352.63 on Thursday. The firm has a market capitalization of $134.85 billion, a P/E ratio of 46.34, a P/E/G ratio of 2.49 and a beta of 0.89. The company has a quick ratio of 1.13, a current ratio of 1.85 and a debt-to-equity ratio of 0.68. The company has a fifty day moving average of $365.79 and a 200 day moving average of $377.86. Stryker Corporation has a 52 week low of $329.16 and a 52 week high of $406.19.

Stryker (NYSE:SYK) last released its quarterly earnings data on Thursday, October 30th. The medical technology company reported $3.19 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.13 by $0.06. The firm had revenue of $6.06 billion for the quarter, compared to analysts’ expectations of $6.04 billion. Stryker had a net margin of 12.07% and a return on equity of 24.07%. The company’s revenue for the quarter was up 10.2% compared to the same quarter last year. During the same quarter in the previous year, the company earned $2.87 earnings per share. Stryker has set its FY 2025 guidance at 13.500-13.600 EPS. On average, research analysts predict that Stryker Corporation will post 13.47 earnings per share for the current year.

Stryker Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, January 30th. Shareholders of record on Wednesday, December 31st will be given a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a yield of 1.0%. The ex-dividend date of this dividend is Wednesday, December 31st. This is a positive change from Stryker’s previous quarterly dividend of $0.84. Stryker’s dividend payout ratio is currently 44.15%.

Insiders Place Their Bets

In related news, CAO William E. Berry, Jr. sold 1,953 shares of the company’s stock in a transaction that occurred on Friday, November 14th. The stock was sold at an average price of $365.49, for a total transaction of $713,801.97. Following the completion of the transaction, the chief accounting officer owned 2,833 shares in the company, valued at $1,035,433.17. This represents a 40.81% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Preston Wendell Wells sold 165 shares of the firm’s stock in a transaction on Thursday, November 20th. The stock was sold at an average price of $365.88, for a total value of $60,370.20. Following the completion of the sale, the chief financial officer directly owned 6,694 shares of the company’s stock, valued at $2,449,200.72. The trade was a 2.41% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 522,118 shares of company stock worth $185,381,932. 5.90% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

SYK has been the subject of several research reports. Sanford C. Bernstein reaffirmed an “outperform” rating on shares of Stryker in a research note on Monday, November 3rd. Needham & Company LLC reaffirmed a “buy” rating and issued a $448.00 price objective on shares of Stryker in a research note on Friday, November 14th. Wells Fargo & Company increased their target price on shares of Stryker from $452.00 to $456.00 and gave the company an “overweight” rating in a report on Friday, November 14th. Barclays lifted their target price on shares of Stryker from $443.00 to $453.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 22nd. Finally, Citigroup cut their price target on shares of Stryker from $455.00 to $420.00 and set a “buy” rating for the company in a research report on Thursday, December 11th. Twelve investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $431.83.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.